outbreak
caus
sever
acut
respiratori
syndrom
coronaviru
continu
endang
global
health
hamper
world
economi
outbreak
start
decemb
wuhan
hubei
provinc
unfortun
current
still
specif
effect
treatment
evid
show
elderli
peopl
infect
cardiovascular
diseas
includ
hypertens
risk
develop
sever
case
hypertens
survey
report
chines
peopl
year
age
hypertens
wherea
preval
hypertens
among
citizen
year
age
ra
play
import
role
regul
electrolyt
balanc
blood
pressur
compris
two
pathway
aceang
pathway
ma
receptor
pathway
normal
physiolog
condit
activ
aceang
axi
ma
receptor
axi
dynam
equilibrium
state
maintain
normal
function
correspond
system
similar
sar
believ
invad
host
cell
entri
receptor
sarscov
infect
reduc
express
result
imbal
aceang
axi
ma
receptor
axi
target
aceang
axi
novel
therapeut
strategi
hypertens
acei
ara
inhibit
aceang
pathway
also
modul
ma
receptor
pathway
dysfunct
reninangiotensin
system
ra
observ
coronaviru
infect
diseas
patient
whether
ra
inhibitor
angiotensinconvert
enzym
inhibitor
acei
angiotensin
ii
type
receptor
blocker
arb
associ
clinic
outcom
remain
unknown
aim
evalu
abil
ra
inhibitor
protect
patient
hypertens
studi
approv
shenzhen
third
peopl
hospit
ethic
committe
verbal
inform
consent
obtain
patient
patient
famili
member
perform
retrospect
review
medic
record
hospit
patient
admit
shenzhen
third
peopl
hospit
januari
februari
inform
patient
hypertens
extract
enrol
patient
review
clinic
data
extract
electron
medic
record
includ
clinic
symptom
sign
laboratori
find
commerci
realtim
pcr
kit
geneodx
co
ltd
shanghai
china
use
detect
sampl
consid
posit
cycl
threshold
valu
ctvalu
less
neg
ctvalu
sampl
ctvalu
requir
confirm
retest
sampl
identifi
posit
local
laboratori
valid
key
laboratori
shenzhen
cdc
sever
wasidentifi
hospit
accord
guidelin
establish
nation
health
commiss
peopl
republ
china
therapeut
regimen
patient
compli
guidelin
establish
nation
health
commiss
peopl
republ
china
hypertens
classifi
grade
grade
grade
accord
guidelin
european
societi
hypertens
esh
hypertens
patient
divid
two
subgroup
base
antihypertens
drug
treatment
detail
inform
enrol
patient
shown
supplementari
tabl
spss
softwar
packag
use
statist
analysi
measur
data
express
median
interquartil
rang
iqr
differ
group
compar
unpair
test
count
data
express
percentag
differ
group
test
chisquar
test
p
consid
statist
signific
total
patient
admit
shenzhen
third
peopl
hospit
februari
among
patient
hypertens
nine
patient
grade
take
antihypertens
drug
hospit
exclud
subsequ
analysi
patient
receiv
antihypertens
therapi
includ
studi
analyz
patient
divid
two
group
base
antihypertens
therapi
aceiarb
group
patient
includ
patient
treat
acei
arb
drug
nonaceiarb
group
patient
includ
patient
treat
antihypertens
drug
includ
calcium
channel
blocker
ccb
diuret
eight
patient
nonaceiarb
group
patient
aceiarb
group
comorbid
type
diabet
coronari
heart
diseas
chd
vast
major
hypertens
patient
receiv
current
therapeut
regimen
shown
supplementari
tabl
one
year
blood
pressur
patient
wellcontrol
therapeut
regimen
hospit
comparison
baselin
characterist
two
group
summar
supplementari
tabl
median
age
analyz
subject
year
iqr
year
male
signific
differ
hypertens
grade
observ
aceiarb
group
nonaceiarb
group
group
show
similar
sign
symptom
median
number
day
onset
symptom
hospit
admiss
nonaceiarb
group
aceiarb
group
meanwhil
median
number
day
symptom
onset
hospit
discharg
day
nonaceiarb
group
day
aceiarb
group
median
heart
rate
respiratori
rate
nonaceiarb
group
bpm
respect
comparison
median
heart
rate
respiratori
rate
nonaceiarb
group
bmp
respect
baselin
characterist
shown
tabl
significantli
differ
two
group
hospit
patient
nonaceiarb
group
categor
sever
subgroup
one
patient
die
contrast
aceiarb
group
patient
categor
sever
subgroup
patient
die
figur
percentag
sever
case
aceiarb
group
higher
nonaceiarb
group
differ
signific
possibl
due
small
number
clinic
case
next
examin
effect
take
acei
arb
drug
laboratori
find
patient
hypertens
shown
figur
b
trend
toward
lower
level
patient
aceiarb
group
mark
variat
creactiv
protein
crp
observ
two
group
figur
b
absolut
number
cell
aceiarb
group
significantli
higher
nonaceiarb
group
signific
chang
cell
count
two
group
figur
c
addit
although
viral
load
differ
two
group
hospit
admiss
peak
viral
load
hospit
aceiarb
group
significantli
lower
nonaceiarb
group
figur
laboratori
find
white
blood
cell
count
neutrophil
count
platelet
count
lactat
dehydrogenas
shown
supplementari
tabl
signific
differ
observ
two
group
report
ra
play
critic
role
regul
hypertens
acut
lung
injuri
caus
virus
sar
chang
ra
activ
relat
pathogenesi
hypertens
inflammatori
lung
diseas
target
ra
effect
antihypertens
therapeut
strategi
acei
arb
inhibit
aceang
system
commonli
use
drug
hypertens
patient
recent
evid
suggest
hypertens
patient
predispos
develop
sever
case
thu
import
determin
effect
ra
inhibitor
patient
hypertens
studi
suggest
patient
increas
angiotensin
ii
compar
healthi
peopl
abnorm
increas
angiotensin
ii
relat
hypertens
lung
failur
addit
ra
inhibitor
shown
associ
reduc
mortal
patient
sepsi
angiotensin
ii
posit
regul
express
inflammatori
cytokin
activ
excess
high
level
inflammatori
cytokin
harm
outcom
patient
thu
suggest
benefici
patient
use
aceisarb
inhibit
ra
howev
confirm
clinic
evid
avail
studi
patient
hypertens
enrol
found
aceiarb
therapi
attenu
inflammatori
respons
potenti
inhibit
level
consist
find
acei
arb
therapi
allevi
lpsinduc
pneumon
injuri
patient
chronic
heart
failur
proven
acei
therapi
associ
decreas
cytokin
ratio
inflammatori
cytokin
product
studi
also
suggest
aceiarb
therapi
benefici
effect
immun
system
avoid
peripher
cell
deplet
furthermor
viral
load
report
highli
correl
sever
lung
injuri
also
observ
aceiarb
therapi
decreas
viral
load
hypothes
ra
inhibitor
directli
inhibit
viral
replic
rather
play
indirect
antivir
role
regul
immun
function
inhibit
inflammatori
respons
mechan
need
clarifi
vitro
vivostudi
futur
taken
togeth
first
clinic
evid
demonstr
ra
inhibitor
improv
clinic
outcom
patient
hypertens
suggest
patient
could
benefit
persist
preferenti
usag
aceiarb
antihypertens
treatment
